10X Genomics, Inc. (TXG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$62.65-0.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TXG
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Revenues | 616.9 | 642.8 | 610.8 | 618.7 | 516.4 | 490.5 | 298.8 | 245.9 |
| Total Revenues | — | — | — | — | — | — | — | 245.9 |
| Cost of Revenues | 184.9 | 198.9 | 196.3 | 209.4 | 120.4 | 74.1 | 58.5 | 61.0 |
| Gross Profit | 432.0 | 443.9 | 414.5 | 409.3 | 396.0 | 416.4 | 240.4 | 184.9 |
| Operating Expenses & Income | ||||||||
| Selling, General & Admin | 297.0 | 316.1 | 344.3 | 343.3 | 298.3 | 257.6 | 202.3 | 130.8 |
| Operating Income | (88.4) | (61.0) | (194.6) | (265.3) | (167.9) | (52.3) | (534.1) | (30.6) |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | — | — | — | 0.0 | 0.5 | 0.9 | 1.7 | 3.1 |
| Interest & Investment Income | 21.9 | 20.0 | 18.4 | 16.9 | 6.6 | 0.2 | 1.5 | 2.8 |
| Net Interest Expenses | — | — | — | (16.9) | (6.2) | 0.7 | 0.2 | 0.3 |
| Other Non-Operating Income / Expenses | 13.5 | 21.1 | 16.9 | 16.6 | 6.0 | (1.5) | (0.3) | (0.5) |
| Asset Writedown | — | — | 3.1 | 9.8 | 0.0 | 0.0 | — | — |
| EBT, Incl. Unusual Items | (74.9) | (39.9) | (177.7) | (248.8) | (162.0) | (53.7) | (534.5) | (31.0) |
| Income Tax Expense | 0.2 | 3.6 | 4.9 | 6.3 | 4.0 | 4.5 | 8.3 | 0.2 |
| Net Income | ||||||||
| Net Income | (75.1) | (43.5) | (182.6) | (255.1) | (166.0) | (58.2) | (542.7) | (31.3) |
| Per Share | ||||||||
| Basic EPS | (0.58) | (0.35) | (1.52) | (2.18) | (1.46) | (0.53) | (5.37) | — |
| Diluted EPS | (0.58) | (0.35) | (1.52) | (2.18) | (1.46) | (0.53) | (5.37) | — |
| Revenue per Share | 4.75 | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 130.0 | 124.7 | 120.5 | 117.2 | 113.9 | 110.3 | 101.2 | — |
| Diluted Weighted Avg Shares | 130.0 | 124.7 | 120.5 | 117.2 | 113.9 | 110.3 | 101.2 | — |
| Supplemental | ||||||||
| EBITDA | — | (24.8) | (158.7) | (229.8) | (142.6) | (31.1) | (520.1) | (23.5) |
| EBIT | (88.4) | (61.0) | (194.6) | (265.3) | (167.9) | (52.3) | (534.1) | (30.6) |
| Effective Tax Rate | -0.3% | — | — | -2.5% | -2.5% | -8.4% | -1.5% | -0.7% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.